Biocure Technology Inc.
BICTF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.38 | -0.18 | 0.20 | 1.60 |
| FCF Yield | 0.00% | -0.23% | -4.18% | -0.72% |
| EV / EBITDA | 0.00 | 0.00 | -29.36 | -74.18 |
| Quality | ||||
| ROIC | -22.89% | -63.95% | 30.00% | -38.80% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.07 | 0.15 | 2.03 | 0.59 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 100.01% | 73.47% | 4.89% | 16.51% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | -0.07 | -2.17 |
| Interest Coverage | -41,200.93 | 0.00 | 0.00 | -35.47 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |